MADRIGAL PHARMACEUTICALS, INC. (MDGL) Stock
1 member of Congress disclosed 1 trade in MDGL since 2023: 0 purchases and 1 sale, most recently Daniel Goldman (sale, Apr 10, 2023). 8 of the hedge funds AlphaScala tracks reported MDGL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Paulson & Co's at $719.52M. Company insiders reported 0 open-market buys and 25 sales on SEC Form 4 in the 90 days to Oct 30, 2026.
Which members of Congress traded MADRIGAL PHARMACEUTICALS, INC. (MDGL)?
Most recent: Daniel Goldman (sale, Apr 10, 2023); records start Apr 10, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-04-10 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026.
See all MDGL political trades →Which hedge funds own MDGL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Paulson & Co John Paulson | 1.34M | $719.52M | -4% |
| Citadel Ken Griffin | 507K | $272.36M | +12% |
| Point72 Steve Cohen | 137K | $73.58M | -39% |
| Marshall Wace | 102K | $54.69M | +365% |
| Millennium Management Israel Englander | 81K | $43.60M | +99% |
| Renaissance Technologies Jim Simons (founder) | 46K | $24.67M | -36% |
| D.E. Shaw David Shaw | 35K | $18.83M | +16% |
| Hussman Investment Trust John Hussman | 2K | $1.13M | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are MADRIGAL PHARMACEUTICALS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 60 | $32K |
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 106 | $57K |
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 218 | $117K |
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 160 | $86K |
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 687 | $371K |
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 368 | $199K |
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 1.2K | $652K |
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 1.5K | $837K |
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 761 | $415K |
| Sep 11, 26 | Sibold William John | President and CEO | SELL | 120 | $66K |
SEC Form 4 filings as of Oct 30, 2026 · not updated for 4 days; newer filings may exist
See cluster-buy signals across all tickers →MDGL price chart
Powered by TradingViewWhat does MADRIGAL PHARMACEUTICALS, INC. do?
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and related liver conditions. Its lead product, Rezdiffra (resmetirom), is a liver-directed thyroid hormone receptor beta agonist approved for treating adults with MASH and moderate to advanced liver fibrosis, marking it as the first FDA-approved therapy in this category. The company has also expanded its pipeline through a global licensing agreement for ervogastat, an oral DGAT-2 inhibitor in Phase 2 development, to complement its MASH treatment offerings. Madrigal Pharmaceuticals, Inc. targets the growing demand in the metabolic liver disease market, where it plays a pioneering role with rapid commercialization efforts, including approvals in the United States and Europe. Headquartered in West Conshohocken, Pennsylvania, and founded in 2000, the company concentrates on addressing unmet needs in cardiovascular, metabolic, and liver diseases through targeted oral therapies.